Key result
This review summarizes current antiplatelet therapies and innovative approaches to targeting protease-activated receptors in patients with atherothrombotic vascular disease.
Answers are grounded in this paper and cite their sources.
This review discusses current antiplatelet therapies and innovative approaches targeting protease-activated receptors (PARs) in atherothrombotic vascular disease.
Platelet activation and thrombus formation play a central role in ischemic vascular disease. Thrombin, an especially potent physiologic agonist mediating in vivo activation of platelets, acts via a unique family of G-protein-coupled receptors called protease-activated receptors (PARs) with a broad tissue expression. This review focuses on current antiplatelet therapies as well as innovative approaches to targeting PARs in patients with atherothrombotic vascular disease.
No takes yet. Share an insight, caveat, or question.
Holinstat et al. (2015) conducted a review in Atherothrombotic vascular disease. Protease-activated receptor (PAR) antagonism was evaluated. This review summarizes current antiplatelet therapies and innovative approaches to targeting protease-activated receptors in patients with atherothrombotic vascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: